Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Key Highlights
- ➤Bicara grants one employee options for 50,000 shares at $7.93 exercise price
- ➤Options vest 25% after one year, then in 12 quarterly installments
- ➤Award approved under Bicara’s 2026 Inducement Plan pursuant to Nasdaq Rule 5635(c)(4)
- ➤Ficerafusp alfa targets EGFR and TGF-β pathways in solid tumors
BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded an inducement grant on November 2, 2026, to one new employee as a material inducement to employment under Bicara’s 2026 Inducement Plan.
The employee received a non-qualified stock option to purchase 50,000 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $7.93 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq on November 2, 2026. One-fourth of the options vest on the first anniversary of the employee’s applicable start date, with the remaining options vesting in 12 equal quarterly installments thereafter, subject to the employee’s continued service with the company through each applicable vesting date.
Get started
Create a free account to read the full story.